#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	13856	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2083	660.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1430	1430	C	793	C	753	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25690	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3451	740.4	0	.	n	.	0	T695C	SNP	695	695	T	974	974	C	766	C,T	726,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25690	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3451	740.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1616	1616	A	903	A	850	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25690	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3451	740.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2250	2250	C	880	C	824	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25690	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3451	740.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2324	2324	A	827	A	789	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25690	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3451	740.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2876	2876	C	773	C	726	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2066	folP	852	852	100.0	folP.l15.c4.ctg.1	1421	144.3	1	SNP	p	R228S	1	.	.	682	684	AGC	964	966	AGC	217;221;219	A;G;C	208;209;209	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4966	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3396	145.8	1	SNP	p	S91F	0	.	.	271	273	TCC	600	602	TCC	142;139;140	T;C;C,A	134;133;132,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4966	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3396	145.8	1	SNP	p	D95G	0	.	.	283	285	GAC	612	614	GAC	140;142;143	G;A;C	130;131;129	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4966	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3396	145.8	1	SNP	p	D95N	0	.	.	283	285	GAC	612	614	GAC	140;142;143	G;A;C	130;131;129	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1510	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1318	114.1	0	.	p	.	0	A39T	NONSYN	115	117	GCC	463	465	ACC	177;177;176	ACC,ACCC;C;C	163,1;169;168	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1510	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1318	114.1	0	.	p	.	0	R44H	NONSYN	130	132	CGC	478	480	CAC	165;166;166	C;A;C	154;154;156	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1510	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1318	114.1	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	661	663	CAC	199;199;203	C;A;C	190;186;192	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1510	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1318	114.1	1	SNP	p	G45D	0	.	.	133	135	GGC	481	483	GGC	167;172;175	G;G;C	157;162;163	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	862	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	948	89.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5078	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3000	168.8	1	SNP	p	D86N	0	.	.	256	258	GAC	617	619	GAC	215;215;217	G;A;C	203;195;205	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5078	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3000	168.8	1	SNP	p	S87I	0	.	.	259	261	AGT	620	622	AGT	217;217;215	A;G;T	202;207;203	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5078	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3000	168.8	1	SNP	p	S87R	0	.	.	259	261	AGT	620	622	AGT	217;217;215	A;G;T	202;207;203	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5078	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3000	168.8	1	SNP	p	S87W	0	.	.	259	261	AGT	620	622	AGT	217;217;215	A;G;T	202;207;203	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5078	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3000	168.8	1	SNP	p	S88P	0	.	.	262	264	TCC	623	625	TCC	217;217;217	T;C;C	204;205;205	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4140	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2522	163.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1530	1532	GGC	221;217;215	G;G;C	200;200;194	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3922	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2512	155.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1333	1335	GCA	226;225;226	G,A;C;A	206,1;209;212	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3922	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2512	155.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1336	1338	ATC	221;222;219	A;T;C	207;209;205	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3922	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2512	155.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1348	1350	GTG	221;221;220	G;T;G	207;204;206	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3922	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2512	155.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1348	1350	GTG	221;221;220	G;T;G	207;204;206	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3922	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2512	155.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1852	1854	ACC	213;212;213	A;C;C	185;189;190	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3922	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2512	155.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1906	1908	GCG	194;192;189	G;C,G;G	167;153,1;161	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3922	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2512	155.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1906	1908	GCG	194;192;189	G;C,G;G	167;153,1;161	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3922	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2512	155.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2029	2031	GGC	156;157;155	G;G;C	142;139;141	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3922	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2512	155.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2038	2040	GGC	146;146;146	G;G;C	129;130;128	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3922	penA	1749	1749	100.0	penA.l15.c30.ctg.1	2512	155.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2056	2058	CCG	119;121;122	C,G;C,G;G	92,2;93,1;95	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5770	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3172	181.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2152	porA	1146	1146	99.83	porA.l6.c17.ctg.1	1736	123.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	522	522	C	157	C	150	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	246	porB1a	984	268	90.44	porB1a.l15.c30.ctg.2	317	23.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	74	76	AAT	15;15;15	A;A;T	12;12;12	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	246	porB1a	984	268	90.44	porB1a.l15.c30.ctg.2	317	23.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	77	79	AAT	15;15;15	A;A;T	12;12;12	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	246	porB1a	984	268	90.44	porB1a.l15.c30.ctg.2	317	23.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	101	103	GCA	12;12;13	G;C;A	11;11;12	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	246	porB1a	984	268	90.44	porB1a.l15.c30.ctg.2	317	23.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	124	126	GTA	11;11;11	G;T;A	10;11;11	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	246	porB1a	984	268	90.44	porB1a.l15.c30.ctg.2	317	23.0	0	.	p	.	0	N237fs	FSHIFT	709	709	A	133	133	A	11	A	11	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2816	porB1b	1038	1038	99.52	porB1b.l15.c17.ctg.1	1354	205.2	0	.	p	.	0	I45V	NONSYN	133	135	ATT	305	307	GTT	204;204;202	G,A;T;T	198,1;199;198	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2816	porB1b	1038	1038	99.52	porB1b.l15.c17.ctg.1	1354	205.2	0	.	p	.	0	I75V	NONSYN	223	225	ATT	395	397	GTT	225;229;231	G;T;T	208;204;217	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2816	porB1b	1038	1038	99.52	porB1b.l15.c17.ctg.1	1354	205.2	0	.	p	.	0	S89T	NONSYN	265	267	AGC	437	439	ACC	259;261;262	A;C;C	228;244;243	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2816	porB1b	1038	1038	99.52	porB1b.l15.c17.ctg.1	1354	205.2	0	.	p	.	0	I98V	NONSYN	292	294	ATC	464	466	GTC	237;243;242	G;T;C	219;216;221	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2816	porB1b	1038	1038	99.52	porB1b.l15.c17.ctg.1	1354	205.2	1	SNP	p	G120K	1	.	.	358	360	AAG	530	532	AAG	239;237;234	A,G;A;G	222,1;226;221	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2816	porB1b	1038	1038	99.52	porB1b.l15.c17.ctg.1	1354	205.2	1	SNP	p	A121N	1	.	.	361	363	AAC	533	535	AAC	239;237;233	A;A;C	225;225;220	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2816	porB1b	1038	1038	99.52	porB1b.l15.c17.ctg.1	1354	205.2	1	SNP	p	N121D	0	.	.	361	363	AAC	533	535	AAC	239;237;233	A;A;C	225;225;220	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10264	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4730	215.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1915	1917	AAT	198;197;194	A,C;A;T	189,1;187;185	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1122	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	1019	109.4	1	SNP	p	V57M	1	.	.	169	171	ATG	512	514	ATG	246;247;249	A;T;G	235;233;233	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
